Cytek Biosciences, Inc (CTKB) Prices 16.7M Share IPO at $17/sh

Cytek Biosciences, Inc. (Nasdaq: CTKB) announced today the pricing of its initial public offering of an aggregate of 16,749,330 shares of its common stock at a price to the public of $17.00 per share. The gross proceeds to Cytek from the offering, before deducting underwriting discounts and commissions and estimated offering expenses, are expected to be $200 million. Cytek is offering 11,764,706 shares of common stock and the selling stockholders named in the prospectus are offering 2,799,929 shares of common stock. Cytek will not receive any proceeds from the sale of shares by the selling stockholders. In addition, Cytek has granted the underwriters a 30-day option to purchase up to an additional 2,184,695 shares of common stock solely to cover over-allotments, if any, at the initial public offering price, less underwriting discounts and commissions. The shares are expected to begin trading on The Nasdaq Global Select Market on July 23, 2021. The offering is expected to close on July 27, 2021, subject to satisfaction of customary closing conditions.

Morgan Stanley, Goldman Sachs & Co. LLC, Piper Sandler & Co. and Cowen are acting as joint book running managers for the offering.

The offering is being made only by means of a prospectus. A copy of the final prospectus related to the offering, when available, may be obtained from Morgan Stanley & Co. LLC, Attn: Prospectus Department, 180 Varick Street, 2nd Floor, New York, NY 10014, by telephone at (866) 718-1649 or by email at [email protected]; Goldman Sachs & Co. LLC, Attn: Prospectus Department, 200 West Street, New York, NY 10282, by telephone at (866) 471-2526 or by email at [email protected]; Piper Sandler & Co., Attn: Prospectus Department, 800 Nicollet Mall, J12S03, Minneapolis, MN 55402, by telephone at (800) 747-3924 or by email at [email protected]; or Cowen and Company, LLC, c/o Broadridge Financial Solutions, Attn: Prospectus Department, 1155 Long Island Avenue, Edgewood, NY 11717, by telephone at (833) 297-2926 or by email at [email protected].

A registration statement relating to these securities has been filed with, and declared effective by, the Securities and Exchange Commission (the “SEC”) on July 22, 2021. A copy of the registration statement may be accessed through the SEC’s website at www.sec.gov. This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

You May Also Be Interested In

• Fisker (FSR) files form 10-K, sees more job cuts, reiterates going concern doubts
• Tungray Technologies (TRSG) Closes $5M IPO
• Orgenesis (ORGS) Files $100M Mixed Shelf